The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...
Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...
NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product ...
3d
Novo Nordisk's deal with Korro is worth a total of $530 million in research and development (R&D) funding, milestone payments ...
Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...
Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...
In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...
“To date, children have had virtually no options for treating obesity,” said Dr. Claudia ... The new study, paid for by Novo ...
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
But there's no guarantee of success here, nor will Novo Nordisk be getting anything tangible yet from its commitment to Korro. Therefore, it's a bit premature to take this latest development as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback